Gold bars to be exempt from tariffs, White House clarifies
Personalis, Inc. (NASDAQ:PSNL), a medical laboratory services company with a market capitalization of $625 million and impressive revenue growth of 15.6% over the last twelve months, announced Tuesday that it has amended its existing commercialization and reference laboratory agreement with Tempus AI, Inc. to include colorectal cancer as a new indication for its NeXT Personal test. The amendment allows Tempus to market the NeXT Personal ultra-sensitive tumor-informed minimal residual disease test for colorectal cancer, in addition to its prior authorizations for breast cancer, lung cancer, and immuno-oncology monitoring.
According to the company’s statement, the amendment also extends the term of the agreement through November 25, 2029. Colorectal cancer is now included as an indication subject to exclusivity, meaning Personalis will not permit third parties, except for an acquirer or its affiliates, to market NeXT Personal for any of the covered indications during the exclusivity period. Tempus, in turn, has agreed not to market any other tumor-informed molecular residual disease assay for these indications. The exclusivity period is extended until December 31, 2028, subject to certain exceptions.
The amendment also changes the term of specific standstill restrictions previously agreed to by Tempus. These restrictions will now expire on the earlier of June 4, 2027, or the expiration or termination of the exclusivity period.
Personalis is a medical laboratory services company based in Fremont, California. The information is based on a statement included in a filing with the Securities and Exchange Commission.
In other recent news, Personalis reported strong financial results for the first quarter of 2025, with revenues reaching $20.6 million, surpassing analyst expectations of $17.5 million. The company’s earnings per share (EPS) also exceeded forecasts, reported at -$0.18 compared to the anticipated -$0.25. This positive performance was driven by significant growth in its NeXT Personal molecular tests, which increased by 52% from the previous quarter. In addition, Personalis has extended its strategic collaboration with Tempus for cancer recurrence detection technology through 2029, now including colorectal cancer alongside breast, lung, and solid tumor immunotherapy monitoring. H.C. Wainwright maintained a Buy rating on Personalis and raised its price target from $8.00 to $9.00, reflecting confidence in the company’s growth trajectory. Furthermore, Personalis has revealed that its NeXT Personal ctDNA test can predict cervical cancer progression up to 16 months earlier than imaging methods, based on findings from the phase 3 CALLA study. The company continues to focus on expanding its clinical evidence and achieving broader reimbursement coverage for its MRD testing platform. These developments underscore Personalis’ strategic advancements in the precision oncology field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.